{"result": {"id": "98eab12f-9969-4d58-a1ba-b376a8e914ef", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>LDL-C<|>ORGANIZATION<|>Low-density lipoprotein cholesterol (LDL-C) is a primary target in lipid management, with levels monitored to assess cardiovascular risk and treatment efficacy>  \n##  \n(\"entity\"<|>HMG-COA REDUCTASE<|>ORGANIZATION<|>HMG-CoA reductase is the enzyme targeted by statins to inhibit cholesterol synthesis in the liver>  \n##  \n(\"entity\"<|>LIPOPROTEIN LIPASE<|>ORGANIZATION<|>Lipoprotein lipase is an enzyme activated by ω-3 fatty acids that helps break down triglycerides in the blood>  \n##  \n(\"entity\"<|>CHOLESTEROL ABSORPTION INHIBITOR<|>ORGANIZATION<|>Drugs that block intestinal cholesterol absorption, often combined with statins when LDL-C remains elevated>  \n##  \n(\"entity\"<|>NICOTINIC ACID<|>ORGANIZATION<|>Nicotinic acid (niacin) is a lipid-modifying drug sometimes combined with other agents for severe hypertriglyceridemia>  \n##  \n(\"relationship\"<|>STATINS<|>HMG-COA REDUCTASE<|>Statins work by inhibiting HMG-CoA reductase to reduce cholesterol production<|>9>  \n##  \n(\"relationship\"<|>ω-3 FATTY ACIDS<|>LIPOPROTEIN LIPASE<|>ω-3 fatty acids activate lipoprotein lipase to enhance triglyceride clearance<|>8>  \n##  \n(\"relationship\"<|>CHOLESTEROL ABSORPTION INHIBITOR<|>LDL-C<|>Cholesterol absorption inhibitors help further reduce LDL-C when statins alone are insufficient<|>7>  \n##  \n(\"relationship\"<|>NICOTINIC ACID<|>TG<|>Nicotinic acid can significantly lower triglyceride levels in severe cases<|>6>  \n##  \n(\"relationship\"<|>FENOFIBRATE<|>TG<|>Fenofibrate primarily targets triglyceride reduction in mixed dyslipidemia<|>8>  \n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559220, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 478, "prompt_tokens": 3235, "total_tokens": 3713, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3136}, "prompt_cache_hit_tokens": 3136, "prompt_cache_miss_tokens": 99}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: （3）处方级 ω?3 脂肪酸：处方级 ω?3 脂肪酸可通 过抑制 VLDL?C 生成 、促进 VLDL?C 清除或激活蛋 白脂肪酶活性，降低 TG 水平［56］。ω?3 脂肪酸还具有 抗炎、抗血栓和抗氧化作用，对心律失常、内皮功能 和胰岛素抵抗有积极影响 。尽管 ω?3 脂肪酸对心 血管疾病高危患者有益，但需注意其可能增加心房 颤动风险［57?58］。\n3. 联合用药\n　　联合应用降脂药物是治疗混合型高脂血症的  主要策略，通过不同作用机制，可提高各血脂指标  达标率，减少不良反应 。混合型高脂血症的常用联  合药物治疗方案包括他汀类药物和/或 PCSK9 抑制  剂与 ω?3 脂肪酸或非诺贝特联合，他汀类药物、贝  特类药物与 ω?3 脂肪酸多种药物联合等（表 5）。 应  根据患者具体情况（如血脂水平、心血管疾病风险、 药物耐受性等）选择联合治疗方案 。需注意，多种  降脂药物联合应用需定期监测患者血脂水平、肝肾  功能、肌酶等，以确保治疗的安全性和有效性。\n表5    常见的混合型高脂血症的联合药物治疗方案\n\n方案\t适用情况\t作用\n降胆固醇药物+ \tω?3 脂肪酸a     降胆固醇药物+\n非诺贝特\n贝特类药物+   ω?3 脂肪酸a\n贝 特 类 药 物 + 烟酸类药物\nω?3  脂 肪 酸 a+ 烟酸类药物\t单 用 他 汀 类 药 物 时 TG 1.7~<2.3 mmol/L\n单 用 他 汀 类 药 物 时 TG 2.3~<5.6 mmol/L\nTG≥5.6 mmol/L TG≥5.6 mmol/L\n贝 特 类 药 物 不 耐 受 ， 且 TG≥5.6 mmol/L\tMACE 风险降低\nMACE 风险降低\nTG   降  低  60.8%~ 71.3%\n-\n\nTG 降低>33%\n　　注：MACE 主要不良心血管事件，TG 甘油三酯；- 无相关数据； 各方案中的降胆固醇药物均指中等强度他汀类药物，若患者低密  度脂蛋白胆固醇（LDL?C）不达标，则加用胆固醇吸收抑制剂，若  LDL?C 仍 不 达 标 ，则 加 用 前 蛋 白 转 化 酶 枯 草 溶 菌 素 9 抑 制 剂 ； a  ω?3 脂肪酸均指处方级\n（四）混合型高脂血症的管理流程\n基于循证医学证据和相关指南［6，22，59］，本共识\n　推荐混合型高脂血症管理流程如下：对于 TG 1.7~  5.6 mmol/L 的混合型高脂血症患者，\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>VLDL-C<|>ORGANIZATION<|>VLDL-C is a type of lipoprotein that is involved in the transport of triglycerides in the blood and is targeted by ω-3 fatty acids for clearance or inhibition of generation>  \n##  \n(\"entity\"<|>ω-3 FATTY ACIDS<|>ORGANIZATION<|>Prescription-grade ω-3 fatty acids are used to lower triglyceride levels by inhibiting VLDL-C generation, promoting VLDL-C clearance, and activating lipoprotein lipase activity. They also have anti-inflammatory, antithrombotic, and antioxidant effects, and can positively influence arrhythmias, endothelial function, and insulin resistance>  \n##  \n(\"entity\"<|>PCSK9 INHIBITOR<|>ORGANIZATION<|>PCSK9 inhibitors are a class of drugs that lower LDL cholesterol by increasing the number of LDL receptors on the liver, often used in combination with other lipid-lowering therapies>  \n##  \n(\"entity\"<|>FENOFIBRATE<|>ORGANIZATION<|>Fenofibrate is a fibric acid derivative used to lower triglyceride levels and is often combined with statins or ω-3 fatty acids for mixed dyslipidemia>  \n##  \n(\"entity\"<|>STATINS<|>ORGANIZATION<|>Statins are a class of drugs that lower cholesterol by inhibiting HMG-CoA reductase, commonly used in the treatment of mixed dyslipidemia>  \n##  \n(\"entity\"<|>MIXED DYSLIPIDEMIA<|>EVENT<|>Mixed dyslipidemia is a condition characterized by elevated levels of triglycerides and cholesterol, requiring combination therapy for management>  \n##  \n(\"entity\"<|>MACE<|>EVENT<|>Major Adverse Cardiovascular Events (MACE) include outcomes like heart attack, stroke, or cardiovascular death, which are targeted for reduction in mixed dyslipidemia treatment>  \n##  \n(\"relationship\"<|>ω-3 FATTY ACIDS<|>VLDL-C<|>ω-3 fatty acids inhibit VLDL-C generation and promote its clearance<|>8>  \n##  \n(\"relationship\"<|>ω-3 FATTY ACIDS<|>MIXED DYSLIPIDEMIA<|>ω-3 fatty acids are used in the treatment of mixed dyslipidemia to lower triglyceride levels<|>7>  \n##  \n(\"relationship\"<|>PCSK9 INHIBITOR<|>STATINS<|>PCSK9 inhibitors are often combined with statins to further lower LDL cholesterol in mixed dyslipidemia<|>6>  \n##  \n(\"relationship\"<|>FENOFIBRATE<|>STATINS<|>Fenofibrate is combined with statins to manage mixed dyslipidemia when triglyceride levels are elevated<|>6>  \n##  \n(\"relationship\"<|>STATINS<|>MIXED DYSLIPIDEMIA<|>Statins are a primary treatment for mixed dyslipidemia to lower cholesterol levels<|>8>  \n##  \n(\"relationship\"<|>MIXED DYSLIPIDEMIA<|>MACE<|>Effective management of mixed dyslipidemia reduces the risk of MACE<|>7>  \n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_b508bfe10c54eef7d47bb82fa7f9f8cf797addfb38c510631c79d0879021a60d_v2"}